BRPI0408778A - proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas - Google Patents

proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas

Info

Publication number
BRPI0408778A
BRPI0408778A BRPI0408778-0A BRPI0408778A BRPI0408778A BR PI0408778 A BRPI0408778 A BR PI0408778A BR PI0408778 A BRPI0408778 A BR PI0408778A BR PI0408778 A BRPI0408778 A BR PI0408778A
Authority
BR
Brazil
Prior art keywords
creap
response element
cyclic amp
proteins
gene expression
Prior art date
Application number
BRPI0408778-0A
Other languages
English (en)
Inventor
Vadim Iourgenko
Mark Aron Labow
Chuanzheng Song
Wenjun Zhang
Jian Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0408778A publication Critical patent/BRPI0408778A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)

Abstract

"PROTEìNAS ATIVADORAS DE ELEMENTO DE RESPOSTA à AMP CìCLICA E USO RELACIONADO AS MESMAS". A invenção refere-se a proteínas ativadoras de elemento de resposta à AMP cíclica (proteínas CREAP) recentemente identificadas. é contemplado aqui que as referidas proteínas são alvos de droga adequados para o desenvolvimento de novos terapêuticos para prevenir, tratar ou melhorar condições patológicas relacionadas à ativação anormal de expressão de gene dependente de CRE ou ativação anormal de quimiocinas. A invenção refere-se a métodos para prevenir, tratar ou melhorar as referidas condições patológicas e composições farmacêuticas por conseguinte compreendendo moduladores com efeito inibidor sobre a atividade da proteína CREAP e/ou expressão de gene de CREAP. A invenção também referese a métodos para identificar compostos com utilidade terapêutica para tratar as referidas condições patológicas, compreendendo a identificação de compostos que podem inibir a atividade da proteína CREAP e/ou expressão de gene de CREAP.
BRPI0408778-0A 2003-03-26 2004-03-25 proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas BRPI0408778A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45769503P 2003-03-26 2003-03-26
US46393403P 2003-04-18 2003-04-18
PCT/EP2004/003182 WO2004085646A1 (en) 2003-03-26 2004-03-25 Cyclic amp response element activator proteins and uses related thereto

Publications (1)

Publication Number Publication Date
BRPI0408778A true BRPI0408778A (pt) 2006-03-28

Family

ID=33101294

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408778-0A BRPI0408778A (pt) 2003-03-26 2004-03-25 proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas

Country Status (8)

Country Link
US (1) US20070036810A1 (pt)
EP (1) EP1611239A1 (pt)
JP (1) JP2007523608A (pt)
AU (1) AU2004223739B2 (pt)
BR (1) BRPI0408778A (pt)
CA (1) CA2520001A1 (pt)
MX (1) MXPA05010312A (pt)
WO (1) WO2004085646A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005336514A1 (en) * 2004-09-25 2007-05-17 Novartis Ag TORC polynucleotides and polypeptides, and methods of use
BRPI0616656A2 (pt) * 2005-10-03 2011-06-28 Novartis Ag ativador de membrana conservada de calcineurina (cmac), uma proteìna terapêutica e alvo
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
WO2014001576A2 (en) * 2012-06-30 2014-01-03 Meyer Helmut E Marker sequences for parkinson's disease and use thereof
WO2023214183A2 (en) 2022-05-06 2023-11-09 Antibody Analytics Limited Chemically induced proximity systems
CN114984224B (zh) * 2022-06-14 2023-10-27 中国中医科学院中药研究所 靶向生物标志物的试剂在制备缓解/治疗神经病理性疼痛药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003652A2 (en) * 1996-07-23 1998-01-29 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services P300/cbp-associated transcriptional co-factor p/caf and uses thereof
AU2001245280A1 (en) * 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002072770A2 (en) * 2001-03-08 2002-09-19 Curagen Corporation Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003004645A1 (en) * 2001-07-03 2003-01-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of cancer involving the notch pathway

Also Published As

Publication number Publication date
EP1611239A1 (en) 2006-01-04
JP2007523608A (ja) 2007-08-23
AU2004223739B2 (en) 2008-04-24
WO2004085646A1 (en) 2004-10-07
US20070036810A1 (en) 2007-02-15
AU2004223739A1 (en) 2004-10-07
CA2520001A1 (en) 2004-10-07
MXPA05010312A (es) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
BR0308081A (pt) Inibidores de histona desacetilase
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
BRPI0511527A (pt) compostos e composições como moduladores de ppar
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
BR0008440A (pt) Inibidor de metaloprotease de sulfamato do ácido hidroxâmico
FI951298A (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.